Nvidia, which importantly commands an S&P 500 weighting of around 7%, touched an intraday high near $144.50 on Tuesday. That breakout to a fresh record was closely-watched says Jonathan Krinsky, chief ...

BTIG analysts downgraded Deckers Outdoor (NYSE:DECK) from Buy to Neutral on Tuesday, citing signs of slowing growth across ...

The October 22 report on Hoka noted signs that the running footwear brand’s multi-year growth is moderating. The firm also ...

The U.S. stock market is now approaching the end of what is typically the most volatile period of a presidential election ...

BTIG’s Jonathan Krinsky made a case that the S&P 500 utility sector may be poised for a downward correction. “We think it's ...

BTIG raised the firm’s price target on MicroStrategy (MSTR) to $240 from $180 and keeps a Buy rating on the shares. The implied bitcoin ...

BTIG downgraded Deckers Outdoor (DECK) to Neutral from Buy without a price target The firm sees the stock’s risk/reward as balanced ...

On Friday, BioNano Genomics Inc (BNGO) stock saw a modest uptick, ending the day at $0.33 which represents no change from the prior close of of $0.33. The stock opened at $0.33 and touched a low of $0 ...

BTIG analyst sees upside in Affirm stock to $68. The fintech is fully committed to soon becoming a profitable company.

BTIG Research reissued their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Friday morning, Marketbeat.com reports. BTIG Research currently has ...

On Monday, BTIG reiterated a Neutral rating on Ally Financial (NYSE: NYSE:ALLY) shares, citing challenges in the near term regarding the company's credit trends and net interest margins.

As of September 25, 2024, the average one-year price target for Apyx Medical is $3.57/share. The forecasts range from a low of $2.02 to a high of $6.30. The average price target represents an ...